In addition to posttranscriptional down regulation, we also investigated the possibility that RGS5 might be targeted by loss-of-function mutations but sequencing of a panel of cell lines revealed no mutations, in keeping with low mutation rate in neuroblastoma [11], which was published following our RGS5 sequencing analysis. This evidence concerns the gene RGS5 and neuroblastoma.